Calistoga Pharmaceuticals, Inc.: Series C $40M

Posted in I - Series C, Q - 3Q10, R - NORTH WEST, X - Inflammation, X - Oncology, X - PI3K, XX - WA

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

Aug

2010

Reata Pharmaceuticals, Inc.: Series D $78M

Posted in I - Series D, Q - 3Q10, R - SOUTH WEST, X - Inflammation, X - Renal, XX - TX

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

Jul

2010

Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Jul

2010

TPP Global Development, Ltd.: Series A $12.2M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - CNS, X - Inflammation, X - Oncology

TPP Global Development (United Kingdom) a preclinical-stage drug development company focused on acquiring and developing early-stage intellectual property in the CNS, inflammation and oncology sectors, closed a $12.2M Series A financing. Participants include Scottish Venture Fund.

Jul

2010

Action Pharma, A/S: Series C $6.3M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Inflammation, X - Renal

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Jun

2010

BIND Biosciences, Inc.: Series C $12.4M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Inflammation, X - Oncology, X - Therapeutic Platform, XX - MA

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

Jun

2010

Logical Therapeutics, Inc.: Series C $16.9M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - GI, X - Inflammation, X - NSAID, XX - MA

Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.

May

2010

Affimed Therapeutics, AG: Series C $26.4M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Affimed (Germany) a clinical-stage biopharmaceutical company focused on antibody therapeutics for hematological and solid tumors as well as inflammatory disease, closed a $26.4M Series C financing. Participants include Aeris Capital, BioMed Invest, Life Sciences Partners, Novo Nordisk and Orbimed.

Apr

2010

Catabasis Pharmaceuticals, Inc.: Series A $39.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Inflammation, X - Metabolism, XX - MA

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Apr

2010

ProtAb, Ltd.: Series A $1.5M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - RA

ProtAb (Israel) a preclinical-stage biopharmaceutical company developing modulators of cytokine regulation and focused on a monoclonal antibody for the treatment rheumatoid arthritis, closed a $1.5M Series A financing. Participants include Pontifax Fund and Clal Biotechnology Industries.

« Previous Entries

to top of page...